First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2009-04-08 12:52:15Open Document File Size: 353,82 KBShare Result on FacebookCityHorsham / LEFÈVRE ET / Helsinki / Venice / East Hanover / Eppendorf / London / Mountain View / Basel / /CompanyLohmann TherapieSysteme AG / Novartis Pharmaceuticals Corporation / From Novartis Pharma AG / Richmond Pharmacology Ltd / Exelon / Pharsight Corp / Novartis Pharma AG / /ContinentAsia / Europe / /CountryGermany / Switzerland / France / Japan / United States / United Kingdom / / /EventProduct Issues / FDA Phase / /FacilityAmerican College of Clinical Pharmacology / St. George’s University of London / /IndustryTermsample solution / treatment of AD and Parkinson’s disease / atmospheric pressure chemical ionization mode / study protocol / food / molar physostigmine solution / study site / supernatant solution / /MedicalConditiondementia / headache / lzheimer’s disease / nausea / AChE / diarrhea / Parkinson’s disease dementia / abdominal pain / Alzheimer’s disease / disease / Nervous system disorders / erythema / vomiting / Parkinson’s disease / irritation / deficiency / dizziness / disorders / /OrganizationRavenscourt Ethics Committee / University of London / London / the American College / World Medical Association / /PersonG. Lefèvre / Ulrike Lorch / Cyriaque Sagan / Silke Appel-Dingemanse / Monika Büche / Greg Se / Albert Enz / Novel Rivastigmine Patch Gilbert Lefèvre / Steve Maton / Greg Sedek / /Positioninvestigator / Advisor / /Productpseudo / Rivastigmine / donepezil / Exelon / Latin America / United States / neuronal signaling / /ProgrammingLanguageJ / /ProvinceOrStateNew Jersey / California / /RegionLatin America / /Technologystudy protocol / PHARMACOKINETICS / drug delivery / PHARMACODYNAMICS / /SocialTag |